- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07392229
Zanubritnib och Anti-MAG-neuropati (MAZINGA)
Zanubrutinib, en andra generationens BTK-hämmare, vid anti-MAG antikroppsneuropati: en fas II italiensk multicentrisk klinisk prövning (MAZINGA)
The MAZINGA study is a multicenter, open-label, single-arm Phase IIA clinical trial designed to evaluate the efficacy, safety, and tolerability of zanubrutinib in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) antibody-associated demyelinating polyneuropathy. Anti-MAG neuropathy is a rare immune-mediated disorder frequently associated with IgM monoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS), Waldenström macroglobulinemia, marginal zone lymphoma, chronic lymphocytic leukemia, and other indolent B-cell lymphoproliferative disorders.
The primary objective of the study is to determine whether 12 months of treatment with zanubrutinib leads to a clinically meaningful neurological improvement, defined as an improvement of at least one point in at least two validated neurological scales. These include reductions in the Overall Neuropathy Limitations Scale (ONLS), INCAT Disability Score, and INCAT Sensory Sum Score (ISS), along with increases in the Medical Research Council (MRC) sum score and the I-RODS functional score.
Secondary objectives include the evaluation of neurophysiological improvement assessed by nerve conduction studies (ENG/EMG), particularly changes in distal motor latency, terminal latency index, and sensory action potential amplitude at 12, 24, and 48 months. Additional secondary endpoints assess hematological efficacy through overall response rate (complete response, very good partial response, or partial response), event-free survival, time to neurological progression, and overall survival. The safety profile of zanubrutinib will be characterized by the incidence, type, and severity of adverse events, serious adverse events, and events of special interest.
Eligible participants are adults (≥18 years) with a confirmed diagnosis of anti-MAG IgM-associated demyelinating polyneuropathy, evidence of a relevant IgM monoclonal gammopathy, elevated anti-MAG antibody titers, and measurable neurological disability. Both treatment-naïve and relapsed/refractory patients are eligible. Key exclusion criteria include prior treatment with BTK inhibitors, aggressive lymphomas, significant axonal damage, uncontrolled comorbidities, active infections, pregnancy, or conditions that could interfere with study participation or safety evaluation.
The planned sample size is approximately 50 patients recruited from nine Italian centers. Statistical analyses will compare neurological outcomes with historical controls, estimate survival endpoints using Kaplan-Meier methods, and explore associations between clinical outcomes and molecular features. This study aims to provide robust prospective evidence on the role of BTK inhibition in anti-MAG neuropathy and to inform future therapeutic strategies for this rare and disabling condition.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Andrea Visentin, Dr, Medical Doctor
- Telefonnummer: +39 049 821 2298
- E-post: ANDREA.VISENTIN@UNIPD.IT
Studera Kontakt Backup
- Namn: Manuela Taurisano, Pharmacy, PhD
- Telefonnummer: +39 3513590476
- E-post: mtaurisano@clinopshub.com
Studieorter
-
-
Milan
-
Milan, Milan, Italien, 20162
- Rekrytering
- CTU Ematologia, Grande Ospedale Metropolitano Niguarda
-
Huvudutredare:
- Anna Maria Frustaci, MD
-
Kontakt:
- Anna Maria Frustaci, MD, Medical Degree (Hematology)
- Telefonnummer: +390264442668
- E-post: annamaria.frustaci@ospedaleniguarda.it
-
Kontakt:
- Lucia Bacigaluppi
- Telefonnummer: +390264447597
- E-post: lucia.bacigaluppi@ospedaleniguarda.it
-
Milan, Milan, Italien, 20089
- Rekrytering
- Neuroimmunology and neuromuscular disease unit, IRCCS Ospedale Clinico Humanitas di Rozzano, Milano
-
Kontakt:
- Pietro Emiliano Doneddu, MD, Medical Degree (Neurology)
- Telefonnummer: (+39) 0282247761
- E-post: pietro.doneddu@hunimed.eu
-
-
PD
-
Padova, PD, Italien, 35128
- Rekrytering
- UOC Ematologia, Azienda Ospedale Università Padova
-
Huvudutredare:
- Andrea Visentin, MD
-
Kontakt:
- Andrea Visentin, MD, Medical Degree (Hematology)
- Telefonnummer: +39 049 821 2298
- E-post: andrea.visentin@aopd.veneto.it
-
-
PV
-
Pavia, PV, Italien, 27100
- Rekrytering
- SC Ematologia 1 - Fondazione IRCCS Policlinico San Matteo
-
Kontakt:
- Martina La Fauci
- Telefonnummer: +39 0382503084
- E-post: cto-oh@smatteo.pv.it
-
Huvudutredare:
- Marzia Varettoni, MD
-
-
RM
-
Roma, RM, Italien, 00168
- Rekrytering
- UOSD Leucemia Linfatica Cronica, Fondazione Policlinico Universitario "A. Gemelli", IRCCS
-
Kontakt:
- Florenzia Vuono
- Telefonnummer: +39 0630157833
- E-post: florenzia.vuono@policlinicogemelli.it
-
Huvudutredare:
- Luca Laurenti, MD
-
-
TO
-
Torino, TO, Italien, 10126
- Rekrytering
- SC Ematologia U, Ospedale Molinette, Torino (TO)
-
Kontakt:
- Simone Ferrero, MD, Medical Degree (Hematology)
- Telefonnummer: +39 0116334220
- E-post: simone.ferrero@unito.it
-
-
Trieste
-
Trieste, Trieste, Italien, 34129
- Rekrytering
- SC UCO Ematologia, Ospedale Maggiore di Trieste
-
Huvudutredare:
- Francesco Zaja, MD
-
Kontakt:
- Francesco Zaja, Prof., Medical Degree (Hematology)
- Telefonnummer: +390403992015
- E-post: francesco.zaja@asugi.sanita.fvg.it
-
Kontakt:
- Maria Chiara Rossetti
- Telefonnummer: + 390403992897
- E-post: mariachiara.rossetti@asugi.sanita.fvg.it
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria (MAIN):
- age ≥18 years;
- diagnosis of anti-MAG antibody polyneuropathy;
- neurophysiological (ENG/EMG) evidence of a demyelinating polyneuropathy with evidence of disproportionately prolonged distal motor latency in one or more nerves -excluding the median nerve if related to carpal tunnel syndrome
- IgM monoclonal protein underlying MGUS (based on the WHO definition of clonal lympho- plasmocytes <10%), Waldenstrom macroglobulinemia (based on the WHO definition of clonal lympho-plasmocytes ≥10%), marginal zone lymphoma, chronic lymphocytic leukemia or low- grade lymphoma not otherwise specified;
- presence of anti MAG antibodies (titer ≥ 7.000 BTU);
- neurophysiological (ENG/EMG) evidence of demyelinating polyneuropathy.
Exclusion Criteria (MAIN):
- Previous treatment with BTK inhibitors
- Aggressive non-Hodgkin lymphoma or IgM multiple myeloma
- Evidence of moderate or severe motor nerve axonal damage, defined when occurring diffuse polyneuropathic denervation or a recruitment pattern lower than intermediate in ≥50% of muscles examined, and/or INCAT at lower limbs ≥4.
- ECOG >3
- Use of strong CYP3A inducers within 14 days prior to the first dose of zanubrutinib
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Treatment arm
Zanubrutinib |
ZANUBRUTINIB ORAL CAPSULES or Brukinsa Oral Capsule |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Andelen patienter med neurologisk förbättring definierad som förbättring med minst 1 poäng efter 12 månaders behandling med zanubrutinib.
Tidsram: 5 år
|
5 år
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- MAZ-01
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .